Jonathan Brown

[Rebecca 💙 🇺🇦 @RFrise00]

https://t.co/lOJ1d5DoTW
5 first authors, a true representation of the team effort, well done every1
@PeacockFlu @influenzal @jacky_paburaw
L Baillon, @Olivia__Swann, R Kugathasan, R Penn,
@joncbrown90 @ry_sanchezdavid J Hazzard,
@EccoStaller @wendybarclay11

[bioRxiv @biorxivpreprint]

Inactivation of SARS-CoV-2 in chlorinated swimming pool water https://t.co/JmZdCCtApR #bioRxiv

[Tom Burgoyne @BioBurgoyne]

Our SARS-CoV-2 preprint is online https://t.co/9aH77PF9bA. We show new insight into attachment, entry and budding of virions in human airway epithelium. I’m very grateful to those that have contributed to this work @Cellfie3 @joncbrown90 @wendybarclay11 @AranSinga @drAnand_Shah_

[Rachel Edgar 💙 @RachelSEdgar]

More research to do, but it’s a start! Many thanks to everyone who worked on this study ⁦@FinolaMRyan⁩ ⁦@ImperialMed⁩ ⁦@ImperialInfect⁩ https://t.co/MVNqbBDQ1Y

[The BMJ @bmj_latest]

NEW #BMJresearch evaluated the performance of new lateral flow immunoassays for use in national covid-19 seroprevalence surveys.

One new LFIA was found to be suitable, but none of the LFIAs tested meet the criteria for individual use https://t.co/ijoT6DAVA0

[Helen Ward @profhelenward]

Latest results of REACT-2 study out today (preprint, not peer reviewed). Antibody self-testing in 150,000 adults in England 26 Jan - 8 Feb 2021
https://t.co/6c0rZ5Bs31

Key results in this thread 1/n
@grahamscooke @SRileyIDD @rozredd

[The Lancet @TheLancet]

NEW Correspondence reports early findings from study suggesting individuals with previous #COVID19 infection generate stronger immune response to first dose of BNT162b2 #vaccine compared with previously uninfected individuals. Responses weaker in over 50s. https://t.co/dZGxmp0cM2

[Michelle Willicombe @mkwillicombe]

Study on vaccine responses in healthcare workers (mostly renal!). Results will enable us to understand/compare how kidney and immunosuppressed transplant patients will respond. https://t.co/4ws53J6YMA . Results to follow very soon! @Maria_Prend @clclarke227 @stephenmcadoo

[Jonathan Brown @joncbrown90]

SARS-CoV-2 variants continue to emerge. Some spread while others die out. So what virological traits might give a variant an advantage over the crowd? Here are our preliminary efforts in the Barclay lab to characterise the B.1.1.7 UK variant
https://t.co/2lTCtBFZS8